ReviewHarm reduction journal2019
Snus: a compelling harm reduction alternative to cigarettes.
Review in Harm reduction journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Oral nicotine pouches for cessation or reduction of use of other tobacco or nicotine products.The Cochrane database of systematic reviews · 2025Pooled it
- Interventions for smokeless tobacco use cessation.The Cochrane database of systematic reviews · 2025Pooled it
- Oral nicotine pouches for cessation or reduction of use of other tobacco or nicotine products.The Cochrane database of systematic reviews · 2025Pooled it
- The health impact of smokeless tobacco products: a systematic review.Harm reduction journal · 2021Pooled it
- Potential effects of using non-combustible tobacco and nicotine products during pregnancy: a systematic review.Harm reduction journal · 2020Pooled it
- A randomised study to assess the nicotine pharmacokinetics of an oral nicotine pouch and two nicotine replacement therapy products.Scientific reports · 2022Trial
- A Randomised Study to Investigate the Nicotine Pharmacokinetics of Oral Nicotine Pouches and a Combustible Cigarette.European journal of drug metabolism and pharmacokinetics · 2022Trial
- Product acceptance and cigarette reduction: Results from a Velo® pouch actual use study among United States adults who smoke.Preventive medicine reports · 2026Article
- A Narrative Review of the Potential Impact of Next-Generation Tobacco and Nicotine Products on Cardiovascular Health.Cureus · 2026Review
- Associations between common mental disorders, cardiovascular risk factors and lifestyle in adults participating in targeted health dialogues in Sweden.Preventive medicine reports · 2026Article
- The emerging role of oral nicotine pouches in tobacco harm reduction.Internal and emergency medicine · 2026Review
- Nicotine pouches: an aid in smoking cessation, or a new public health hazard?Internal and emergency medicine · 2026Review
- Clinical and histopathological manifestations of snus use in Germany: parallels to betel nut-related oral submucous fibrosis in Asia.Virchows Archiv : an international journal of pathology · 2026Article
- Cross-Sectional Study on Oral Nicotine Product Sales Trends in Scandinavia From 2018 to 2025.JMIR public health and surveillance · 2026Article
- Nicotine pouches, oral cancer and tobacco harm reduction: current evidence and research priorities.Frontiers in oral health · 2026Review
- Electronic Nicotine Delivery Devices: What We Know and Its Implications for India Electronic Nicotine Delivery Devices.Indian journal of psychological medicine · 2025Article
- Review
- Article
- Comparing smoking-related disease rates from e-cigarette use with those from tobacco cigarette use: a reanalysis of a recently-published study.Harm reduction journal · 2025Article
- Randomized crossover clinical studies to assess abuse liability and nicotine pharmacokinetics of Velo Oral Nicotine pouches.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Snus is an oral smokeless tobacco product which is usually placed behind the upper lip, either in a loose form or in portioned sachets, and is primarily used in Sweden and Norway. The purpose of this review is to examine the reported effects of snus use in relation to specified health effects, namely lung cancer, cardiovascular disease, pancreatic cancer, diabetes, oral cancer and non-neoplastic oral disease. The review also examines the harm reduction potential of snus as an alternative to cigarettes by comparing the prevalence of snus use and cigarette smoking, and the reported incidence of tobacco-related diseases across European Union countries. The scientific literature generally indicates that the use of snus is not a significant risk factor for developing lung cancer, cardiovascular disease, pancreatic cancer or oral cancer. Studies investigating snus use and diabetes have reported that high consumption of snus (estimated as being four or more cans per week) may be associated with a higher risk of developing diabetes or components of metabolic syndrome; however, overall results are not conclusive. Snus use is associated with the presence of non-neoplastic oral mucosal lesions which are reported to heal rapidly once use has stopped. The most recent Eurobarometer data from 2017 reported that Sweden had the lowest prevalence of daily cigarette use in the European Union at 5% whilst daily "oral tobacco" use was reported to be 20%. European data published by the World Health Organisation in 2018 indicated that Sweden had the lowest rate of tobacco-related mortality and the lowest incidence of male lung cancer. Overall, prevalence statistics and epidemiological data indicate that the use of snus confers a significant harm reduction benefit which is reflected in the comparatively low levels of tobacco-related disease in Sweden when compared with the rest of Europe. The available scientific data, including long-term population studies conducted by independent bodies, demonstrates that the health risks associated with snus are considerably lower than those associated with cigarette smoking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.